ReviewDiscover oncology2026
The impact of statins on prognostic outcomes in patients with non-metastatic solid cancers: a systematic review and meta-analysis.
Review in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundStatins are commonly prescribed low-density lipoprotein-lowering drugs that have been used in patients with cancer due to their pleiotropic effects. In this paper, the association between statin use and prognostic outcomes was examined in patients with non-metastatic solid cancer.
methodsIn accordance with the PRISMA guidelines, a systematic review of the literature was conducted, and meta-analyses of time-to-event outcomes were performed. The literature search was designed using the Participants, Intervention, Comparator, and Outcome (PICO) framework. The search was completed across three different databases: PubMed, The Cochrane Library, and Web of Science. Studies investigating the impact of statin use versus no statin use on oncological survival measures in patients with non-metastatic solid cancers were eligible for inclusion. The outcomes of interest were overall survival (OS), disease-free survival (DFS), recurrence-free survival (RFS), and cancer-specific survival (CSS). Furthermore, the impact of statin use on the tumor microenvironment was an outcome of interest. The risk of bias was assessed using the Newcastle-Ottawa Scale and the quality of the cumulative evidence was evaluated using the modified GRADE approach.
findingsA total of 4,131 articles were title and abstract screened of which 106 articles were included in the systematic review and 90 articles in the meta-analysis. The total number of included patients in the meta-analysis was 472,004 Statin use in patients with non-metastatic solid cancer was significantly associated with improved OS (hazard ratio (HR) = 0.84, 95% confidence interval (CI): 0.80–0.88, I2: 89%), RFS (HR = 0.78, 95% CI: 0.69–0.88, I2: 84%), and CSS (HR = 0.86, 95% CI: 0.81–0.91, I2: 81%). Statin use showed significantly improved OS in patients with gastrointestinal cancer (HR = 0.79, 95% CI: 0.72–0.87, I2: 88%), urological cancer (HR = 0.85, 95% CI: 0.77–0.94, I2: 86%), and gynecological cancer (HR = 0.84, 95% CI: 0.74–0.95, I2: 0%). Conclusions. Statin therapy was associated with improved survival outcomes in patients with non-metastatic solid cancer, especially in gastrointestinal, urological and gynecological cancers.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.